Joseph P. Hagan - 12 Jan 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President and CEO, Director
Signature
Christopher Aker, Attorney in Fact
Issuer symbol
RGLS
Transactions as of
12 Jan 2022
Net transactions value
+$21,520
Form type
4
Filing time
26 Jan 2022, 15:13:34 UTC
Previous filing
04 Jan 2022
Next filing
11 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Purchase $21,520 +100,000 +32% $0.2152 417,006 26 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +1,600,000 $0.000000 1,600,000 12 Jan 2022 Common Stock 1,600,000 $0.2600 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.